Infectious complications after chemotherapy and stem cell transplantation in multiple myeloma: Implications of Fc gamma receptor and myeloperoxidase promoter polymorphisms

References

• Augustson B M, Begum G, Dunn J A, Barth N J, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 – Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23: 9219–9226
   PubMed Web of Science ®Google Scholar
• Cesana C, Nosari A M, Klersy C, Miqueleiz S, Rossi V, Ferrando P, et al. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules. Haematologica 2003; 88: 1022–1028
   PubMed Web of Science ®Google Scholar
• Hargreaves R M, Lea J R, Griffiths H, Faux J A, Holt J M, Reid C, et al. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol 1995; 48: 260–266
   PubMed Web of Science ®Google Scholar
• Mozaffari F, Hansson L, Kiaii S, Ju X, Rossmann E D, Rabbani H, et al. Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br J Haematol 2004; 124: 315–324
   PubMed Web of Science ®Google Scholar
• Walchner M, Wick M. Elevation of CD8+ CD11b+ Leu-8-T cells is associated with the humoral immunodeficiency in myeloma patients. Clin Exp Immunol 1997; 109: 310–316
   PubMed Web of Science ®Google Scholar
• Brimnes M K, Svane I M, Johnsen H E. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin Exp Immunol 2006; 144: 76–84
   PubMed Web of Science ®Google Scholar
• Perri R T, Hebbel R P, Oken M M. Influence of treatment and response status on infection risk in multiple myeloma. Am J Med 1981; 71: 935–940
   PubMed Web of Science ®Google Scholar
• Mølle I, Peterslund N A, Thiel S, Steffensen R. MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2006; 38: 555–560
   PubMed Web of Science ®Google Scholar
• Mølle I, Steffensen R, Thiel S, Peterslund N A. Chemotherapy-related infections in patients with multiple myeloma: associations with mannan-binding lectin genotypes. Eur J Haematol 2006; 77: 19–26
   PubMed Web of Science ®Google Scholar
• van Sorge N M, van der Pol W L, van de Winkel J G. FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003; 61: 189–202
   PubMed Web of Science ®Google Scholar
• Warmerdam P A, van de Winkel J G, Vlug A, Westerdaal N A, Capel P J. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol 1991; 147: 1338–1343
   PubMed Web of Science ®Google Scholar
• Sanders L A, Feldman R G, Voorhorst-Ogink M M, de Haas M, Rijkers G T, Capel P J, et al. Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect Immun 1995; 63: 73–81
   PubMed Web of Science ®Google Scholar
• Domingo P, Muniz-Diaz E, Baraldes M A, Arilla M, Barquet N, Pericas R, et al. Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. Am J Med 2002; 112: 19–25
   PubMed Web of Science ®Google Scholar
• Bredius R G, Derkx B H, Fijen C A, de Wit T P, de Haas M, Weening R S, et al. Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Dis 1994; 170: 848–853
   PubMed Web of Science ®Google Scholar
• Fijen C A, Bredius R G, Kuijper E J, Out T A, de Haas M, De Wit A P, et al. The role of Fc gamma receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals. Clin Exp Immunol 2000; 120: 338–345
   PubMed Web of Science ®Google Scholar
• Platonov A E, Kuijper E J, Vershinina I V, Shipulin G A, Westerdaal N, Fijen C A, et al. Meningococcal disease and polymorphism of FcgammaRIIa (CD32) in late complement component-deficient individuals. Clin Exp Immunol 1998; 111: 97–101
   Google Scholar
• Platonov A E, Shipulin G A, Vershinina I V, Dankert J, van de Winkel J G, Kuijper E J. Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin Infect Dis 1998; 27: 746–750
   PubMed Web of Science ®Google Scholar
• Wiertsema S P, Veenhoven R H, Walraven V, Uiterwaal C S, Schilder A G, Rijkers G T, et al. Pneumococcal vaccine efficacy for mucosal pneumococcal infections depends on Fcgamma receptor IIa polymorphism. Vaccine 2006; 24: 792–797
   PubMed Web of Science ®Google Scholar
• Yuan F F, Wong M, Pererva N, Keating J, Davis A R, Bryant J A, et al. FcgammaRIIA polymorphisms in Streptococcus pneumoniae infection. Immunol Cell Biol 2003; 81: 192–195
   PubMed Web of Science ®Google Scholar
• Yee A M, Phan H M, Zuniga R, Salmon J E, Musher D M. Association between FcgammaRIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30: 25–28
   PubMed Web of Science ®Google Scholar
• Zhou M J, Lublin D M, Link D C, Brown E J. Distinct tyrosine kinase activation and Triton X-100 insolubility upon Fc gamma RII or Fc gamma RIIIB ligation in human polymorphonuclear leukocytes. Implications for immune complex activation of the respiratory burst. J Biol Chem 1995; 270: 13553–13560
   Google Scholar
• Salmon J E, Edberg J C, Brogle N L, Kimberly R P. Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J Clin Invest 1992; 89: 1274–1281
   Google Scholar
• Ory P A, Clark M R, Kwoh E E, Clarkson S B, Goldstein I M. Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils. J Clin Invest 1989; 84: 1688–1691
   PubMed Web of Science ®Google Scholar
• Bux J, Stein E L, Bierling P, Fromont P, Clay M, Stroncek D, et al. Characterization of a new alloantigen (SH) on the human neutrophil Fc gamma receptor IIIb. Blood 1997; 89: 1027–1034
   PubMed Web of Science ®Google Scholar
• Rekand T, Langeland N, Aarli J A, Vedeler C A. Fcgamma receptor IIIA polymorphism as a risk factor for acute poliomyelitis. J Infect Dis 2002; 186: 1840–1843
   PubMed Web of Science ®Google Scholar
• Van Schooten F J, Boots A W, Knaapen A M, Godschalk R W, Maas L M, Borm P J, et al. Myeloperoxidase (MPO) -463G->A reduces MPO activity and DNA adduct levels in bronchoalveolar lavages of smokers. Cancer Epidemiol Biomarkers Prev 2004; 13: 828–833
   PubMed Web of Science ®Google Scholar
• Schabath M B, Spitz M R, Hong W K, Delclos G L, Reynolds W F, Gunn G B, et al. A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer 2002; 37: 35–40
   PubMed Web of Science ®Google Scholar
• Piedrafita F J, Molander R B, Vansant G, Orlova E A, Pfahl M, Reynolds W F. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996; 271: 14412–14420
   PubMed Web of Science ®Google Scholar
• Rutgers A, Heeringa P, Giesen J E, Theunissen R T, Jacobs H, Tervaert J W. Neutrophil myeloperoxidase activity and the influence of two single-nucleotide promoter polymorphisms. Br J Haematol 2003; 123: 536–538
   PubMed Web of Science ®Google Scholar
• Hoy A, Tregouet D, Leininger-Muller B, Poirier O, Maurice M, Sass C, et al. Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. Eur J Hum Genet 2001; 9: 780–786
   PubMed Web of Science ®Google Scholar
• Costa R N, Conran N, Albuquerque D M, Soares P H, Saad S T, Costa F F. Association of the G-463A myeloperoxidase polymorphism with infection in sickle cell anemia. Haematologica 2005; 90: 977–979
   PubMed Web of Science ®Google Scholar
• Rocha V, Franco R F, Porcher R, Bittencourt H, Silva W A, Jr, Latouche A, et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 100: 3908–3918
   PubMed Web of Science ®Google Scholar
• Hsu P I, Jwo J J, Tseng H H, Lai K H, Lo G H, Lo C C, et al. Association of the myeloperoxidase -468G–>A polymorphism with gastric inflammation and duodenal ulcer risk. World J Gastroenterol 2005; 11: 2796–2801
   PubMed Web of Science ®Google Scholar
• Mølle I, Melsvik D, Østergaard M. Rapid single-step methods for detection of two immune defence gene polymorphisms: the myeloperoxidase (MPO) G-129A and the Fc gamma receptor 2A (FCGR2A) H/R131. J Immunol Methods 2007; 324: 105–109
   PubMed Web of Science ®Google Scholar
• Dall'Ozzo S, Andres C, Bardos P, Watier H, Thibault G. Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR. J Immunol Methods 2003; 277: 185–192
   PubMed Web of Science ®Google Scholar
• Bux J, Stein E L, Santoso S, Mueller-Eckhardt C. NA gene frequencies in the German population, determined by polymerase chain reaction with sequence-specific primers. Transfusion 1995; 35: 54–57
   PubMed Web of Science ®Google Scholar
• Kissel K, Hofmann C, Gittinger F S, Daniels G, Bux J. HNA-1a, HNA-1b, and HNA-1c (NA1, NA2, SH) frequencies in African and American Blacks and in Chinese. Tissue Antigens 2000; 56: 143–148
   PubMed Web of Science ®Google Scholar
• Chevrier I, Stucker I, Houllier A M, Cenee S, Beaune P, Laurent-Puig P, et al. Myeloperoxidase: new polymorphisms and relation with lung cancer risk. Pharmacogenetics 2003; 13: 729–739
   PubMedGoogle Scholar
• Papadea C, Reimer C B, Check I J. IgG subclass distribution in patients with multiple myeloma or with monoclonal gammopathy of undetermined significance. Ann Clin Lab Sci 1989; 19: 27–37
   PubMed Web of Science ®Google Scholar